Hypoxic brain injury resulting from cardiac arrest constitutes 76% of all etiologies of disorders of consciousness (DoCs) in patients evaluated by the RECOVER program at the Hospital of the University of Pennsylvania and is among the most prevalent etiologies for DoCs worldwide. Given the inherent uncertainty and overreliance on subjective assessments in many predictions of recovery from DoCs, real-time prognostic tests are crucial in aiding clinical decision-making in evaluating the continuation or withdraw of life- sustaining therapy. This study evaluates the relevance and predictive value of the Neuron-Specific Enolase (NSE), a glycolic enzyme localized in the cytoplasm of neurons and a highly-specific biomarker of neuronal injury, in the prognostication of both acute and long- term cognitive outcomes in cardiac arrest patients with DoCs.